Cabaletta Bio, Inc. (CABA) Financial Ratios
9 years of historical data (2017–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↑
3.40
↑+69% vs avg
5yr avg: 2.02
30Y Low0.6·High3.9
ROE
↓
-127.0%
↑-102% vs avg
5yr avg: -62.9%
30Y Low-127%·High-27%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
CABA Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Cabaletta Bio, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $381M | $224M | $112M | $929M | $271M | $98M | $289M | $76M | — | — |
| Enterprise Value | $326M | $168M | $-36062830 | $741M | $195M | $-24678770 | $187M | $-59802070 | — | — |
| P/E Ratio → | -2.27 | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — |
| P/B Ratio | 3.40 | 2.00 | 0.74 | 3.94 | 2.60 | 0.83 | 2.64 | 0.55 | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
CABA EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — |
CABA Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -127.0% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -127.0% | -127.0% | -59.6% | -39.7% | -47.6% | -40.7% | -26.9% | -26.6% | — | — |
| ROA | -95.9% | -95.9% | -52.8% | -36.5% | -43.5% | -38.4% | -26.0% | -19.3% | -71.4% | -25000.0% |
| ROIC | -429.6% | -429.6% | -361.3% | -147.3% | -341.4% | -1804.9% | -496.0% | -1202.3% | — | — |
| ROCE | -126.2% | -126.2% | -63.3% | -43.3% | -48.0% | -40.7% | -27.3% | -21.8% | -37.6% | — |
CABA Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $83M exceeds total debt of $27M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.24 | 0.24 | 0.10 | 0.02 | 0.05 | — | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.50 | -0.97 | -0.80 | -0.73 | -1.04 | -0.93 | -0.98 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | -0.01 |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | -167.30 | — | — | — | — | — | — | — |
Net cash position: cash ($83M) exceeds total debt ($27M)
CABA Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Cabaletta Bio, Inc.'s current ratio of 2.77x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 15.29x to 2.77x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.77 | 2.77 | 6.15 | 15.29 | 11.47 | 14.86 | 21.92 | 44.66 | 36.05 | 0.00 |
| Quick Ratio | 2.77 | 2.77 | 6.15 | 15.29 | 11.47 | 14.86 | 21.92 | 44.66 | 36.05 | 0.00 |
| Cash Ratio | 2.66 | 2.66 | 6.05 | 15.08 | 11.23 | 14.58 | 20.98 | 43.28 | 35.01 | 0.00 |
| Asset Turnover | — | — | — | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — | — |
CABA Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Cabaletta Bio, Inc. returns 0.1% to shareholders annually primarily through share buybacks.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | 13.2% | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.1% | 0.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.1% | 0.0% | — | — |
| Total Shareholder Yield | 0.1% | 0.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.1% | 13.2% | — | — |
| Shares Outstanding | — | $102M | $49M | $41M | $29M | $26M | $23M | $5M | $15M | $24M |
Peer Comparison
Compare CABA with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 CABAYou | $381M | -2.3 | — | — | — | — | -127.0% | -429.6% | — |
 KYMR | $7B | -23.4 | — | — | 100.0% | -891.3% | -25.8% | -24.9% | — |
 IMVT | $6B | -10.5 | — | — | — | — | -62.5% | — | — |
 ARQT | $3B | -185.9 | — | — | 90.2% | -3.3% | -9.3% | -5.2% | — |
 ROIV | $21B | -120.1 | — | — | 96.9% | -3453.3% | -3.0% | -50.4% | — |
 PRAX | $8B | -25.1 | — | — | — | — | -45.8% | -65.0% | — |
 TGTX | $7B | 279.8 | 158.9 | — | 88.3% | 12.7% | 12.2% | 13.3% | 6.0 |
 BEAM | $3B | -39.9 | — | — | 84.0% | -274.6% | -8.1% | -31.1% | — |
 CRSP | $5B | -8.5 | — | — | -2642.3% | -18933.6% | -30.2% | -27.4% | — |
 EDIT | $311M | -1.8 | — | — | — | — | -198.1% | — | — |
 NTLA | $2B | -3.6 | — | — | — | — | -53.5% | — | — |
| Healthcare Median | — | 22.2 | 14.1 | 18.6 | 64.1% | -5.3% | -34.0% | -11.2% | 3.1 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 9 years · Updated daily
See CABA's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CABA Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare CABA vs KYMR
Side-by-side business, growth, and profitability comparison vs Kymera Therapeutics, Inc..
Start ComparisonCABA — Frequently Asked Questions
Quick answers to the most common questions about buying CABA stock.
What is Cabaletta Bio, Inc.'s P/E ratio?
Cabaletta Bio, Inc.'s current P/E ratio is -2.3x. This places it at the 50th percentile of its historical range.
What is Cabaletta Bio, Inc.'s ROE?
Cabaletta Bio, Inc.'s return on equity (ROE) is -127.0%. The historical average is -52.6%.
Is CABA stock overvalued?
Based on historical data, Cabaletta Bio, Inc. is trading at a P/E of -2.3x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.